167 related articles for article (PubMed ID: 19193430)
1. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer.
Ashton KA; Proietto A; Otton G; Symonds I; McEvoy M; Attia J; Gilbert M; Hamann U; Scott RJ
Gynecol Oncol; 2009 Apr; 113(1):109-14. PubMed ID: 19193430
[TBL] [Abstract][Full Text] [Related]
2. TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.
Zając A; Smolarz B; Stachowiak G; Wilczyński JR
Med Oncol; 2014 Nov; 31(11):286. PubMed ID: 25316267
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
4. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
5. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
7. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
[TBL] [Abstract][Full Text] [Related]
9. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
10. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
11. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.
Do TN; Ucisik-Akkaya E; Davis CF; Morrison BA; Dorak MT
Cancer Genet Cytogenet; 2009 Nov; 195(1):31-6. PubMed ID: 19837266
[TBL] [Abstract][Full Text] [Related]
12. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
[TBL] [Abstract][Full Text] [Related]
13. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
[TBL] [Abstract][Full Text] [Related]
14. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
15. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
16. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.
Marcel V; Palmero EI; Falagan-Lotsch P; Martel-Planche G; Ashton-Prolla P; Olivier M; Brentani RR; Hainaut P; Achatz MI
J Med Genet; 2009 Nov; 46(11):766-72. PubMed ID: 19542078
[TBL] [Abstract][Full Text] [Related]
17. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
Schmidt MK; Reincke S; Broeks A; Braaf LM; Hogervorst FB; Tollenaar RA; Johnson N; Fletcher O; Peto J; Tommiska J; Blomqvist C; Nevanlinna HA; Healey CS; Dunning AM; Pharoah PD; Easton DF; Dörk T; Van't Veer LJ;
Cancer Res; 2007 Oct; 67(19):9584-90. PubMed ID: 17909070
[TBL] [Abstract][Full Text] [Related]
18. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
19. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
[TBL] [Abstract][Full Text] [Related]
20. MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Wang X; Wang YZ; Ma KW; Chen X; Li W
Oncol Res Treat; 2014; 37(4):176-80. PubMed ID: 24732641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]